Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:PTLA's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PTLA Guru Trades in Q1 2016

Steven Cohen 431,200 sh (New)
Jim Simons 474,800 sh (+241.34%)
Paul Tudor Jones 30,442 sh (+24.05%)
Eaton Vance Worldwide Health Sciences Fund 725,700 sh (+52.55%)
Ken Fisher 80,300 sh (unchged)
» More
Q2 2016

PTLA Guru Trades in Q2 2016

Ken Fisher 82,737 sh (+3.03%)
Steven Cohen Sold Out
Paul Tudor Jones 24,761 sh (-18.66%)
Jim Simons 349,400 sh (-26.41%)
Eaton Vance Worldwide Health Sciences Fund 467,200 sh (-35.62%)
» More
Q3 2016

PTLA Guru Trades in Q3 2016

Ken Fisher 82,737 sh (unchged)
Paul Tudor Jones Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Jim Simons 161,500 sh (-53.78%)
» More
Q4 2016

PTLA Guru Trades in Q4 2016

Jim Simons Sold Out
Ken Fisher 46,637 sh (-43.63%)
» More
» Details

Insider Trades

Latest Guru Trades with PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ONCE, NYSE:CBM, NAS:ARRY, NAS:AGIO, NAS:SRPT, NAS:NKTR, NAS:LGND, NAS:LXRX, NAS:HALO, OTCPK:ABCZF, NAS:SAGE, OTCPK:MPSYY, NAS:FPRX, OTCPK:BVNRY, NAS:INVA, NYSE:EBS, NAS:CLVS, NAS:ACOR, NAS:ALDR, OTCPK:BTGGF » details
Traded in other countries:0PP.Germany,
Portola Pharmaceuticals Inc is a biopharmaceutical company. It develops & commercializes novel therapeutics in the areas of thrombosis, other hematologic disorders & inflammation for patients who currently have limited or no approved treatment options.

Portola Pharmaceuticals Inc was incorporated in Delaware in September 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Its two programs address significant unmet medical needs in the areas of thrombosis or blood clots. Its compound Betrixaban is a novel oral once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism, or VTE, in acute medically ill patients. The Company's current product candidates in development includes: Betrixaban, PRT4445, PRT2070, and PRT2607. Betrixaban is a novel oral once-daily inhibitor of Factor Xa in development for extended duration VTE prophylaxis in acute medically ill patients for up to 35 days. PRT4445 is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. PRT2070 is an orally available, potent inhibitor of Syk and JAK. PRT2607 is an orally available, potent and selective inhibitor of Syk. The Company faces competition from large and small pharmaceutical and biotechnology companies, specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies and research institutions and others.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $26.23
EPS (TTM) $ -5.05
Beta1.92
Short Percentage of Float11.20%
52-Week Range $15.68 - 33.68
Shares Outstanding (Mil)56.54

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 26 43 209 389
EPS ($) -5.15 -3.84 -3.84 -3.81
EPS without NRI ($) -5.15 -3.84 -3.84 -3.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)